Nurix Therapeutics Inc

NRIX

16.850USD

+0.900+5.64%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Nurix Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

72 / 392

Overall Ranking

192 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Nurix Therapeutics Inc Highlights

StrengthsRisks

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

Growing

The company is in a growing phase, with the latest annual income totaling USD 83.98M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 83.98M.

Fairly Valued

The company’s latest PE is -5.52, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 87.58M shares, decreasing 7.84% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 553.00 shares of this stock.

Analyst Rating

Based on 17 analysts

Buy

Current Rating

30.000

Target Price

+88.09%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Nurix Therapeutics Inc is 6.99, ranking 172 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 13.58M, representing a year-over-year increase of 2.21%, while its net profit experienced a year-over-year increase of 33.60%.

Score

Industry at a Glance

Previous score

6.99

Change

0



Financials

6.92

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.72

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.53

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.54

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.25

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Nurix Therapeutics Inc is 6.62, ranking 248 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.52, which is -71.89% below the recent high of -1.55 and -75.81% above the recent low of -9.71.

Score

Industry at a Glance

Previous score

6.62

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 72/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Nurix Therapeutics Inc is 8.71, ranking 68 out of 392 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 41.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

8.71

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Nurix Therapeutics Inc is 6.84, ranking 155 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 19.40 and the support level at 15.09, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.46

Change

0.38

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Nurix Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 85.28%, representing a quarter-over-quarter decrease of 1.75%. The largest institutional shareholder is The Vanguard, holding a total of 5.93M shares, representing 5.77% of shares outstanding, with 0.16% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

7.58M

-16.52%

Deep Track Capital LP

6.06M

-0.13%

The Vanguard Group, Inc.

Star Investors

4.47M

+0.52%

BlackRock Institutional Trust Company, N.A.

5.76M

-0.70%

Baker Bros. Advisors LP

3.88M

--

Commodore Capital LP

3.78M

-4.27%

Redmile Group, LLC

3.68M

-1.46%

Vestal Point Capital, LP

3.48M

+73.75%

Pictet Asset Management Ltd.

1.98M

-0.91%

Point72 Asset Management, L.P.

Star Investors

2.87M

-22.47%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Nurix Therapeutics Inc is 4.45, ranking 85 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.97. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Nurix Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Nurix Therapeutics Inc

NRIX

7.00 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment